Published in Melanoma Res on April 01, 2010
The mTOR signalling pathway in human cancer. Int J Mol Sci (2012) 2.38
Targeting BRAF for patients with melanoma. Br J Cancer (2010) 1.56
Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res (2012) 1.52
Metastatic uveal melanoma: biology and emerging treatments. Cancer J (2012) 1.27
Genetic and molecular characterization of uveal melanoma cell lines. Pigment Cell Melanoma Res (2012) 1.23
TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. J Invest Dermatol (2014) 1.21
The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells. Mol Cancer Ther (2014) 0.91
Post-transcriptional regulation in cancer progression : Microenvironmental control of alternative splicing and translation. J Cell Commun Signal (2012) 0.90
The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biol Ther (2011) 0.89
Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma. Oncotarget (2016) 0.85
Bioanalytical method validation of rapamycin in ocular matrix by QTRAP LC-MS/MS: application to rabbit anterior tissue distribution by topical administration of rapamycin nanomicellar formulation. J Chromatogr B Analyt Technol Biomed Life Sci (2012) 0.82
Subtoxic Levels of Apigenin Inhibit Expression and Secretion of VEGF by Uveal Melanoma Cells via Suppression of ERK1/2 and PI3K/Akt Pathways. Evid Based Complement Alternat Med (2013) 0.82
Management of conjunctival malignant melanoma: a review and update. Expert Rev Ophthalmol (2014) 0.80
Conjunctival melanoma and melanocytic intra-epithelial neoplasia. Eye (Lond) (2012) 0.79
GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells. PeerJ (2013) 0.77
Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol (2017) 0.75
A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib. BMC Cancer (2016) 0.75
Distinct stem cells contribute to mammary gland development and maintenance. Nature (2011) 6.32
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene (2003) 3.34
Frequency of TERT promoter mutations in human cancers. Nat Commun (2013) 3.13
The mTOR signalling pathway in human cancer. Int J Mol Sci (2012) 2.38
Identification of stem cell populations in sweat glands and ducts reveals roles in homeostasis and wound repair. Cell (2012) 2.35
BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol (2004) 2.21
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab (2014) 1.71
Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch (2005) 1.62
Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors. Am J Pathol (2002) 1.61
BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab (2004) 1.52
How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer. J Thyroid Res (2011) 1.46
Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid (2007) 1.41
Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol (2004) 1.39
Idiopathic perforation of the gallbladder: a novel differential diagnosis of acute abdomen. J Pediatr Gastroenterol Nutr (2002) 1.33
Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immunohistochemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma. Virchows Arch (2001) 1.30
Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother Radiopharm (2003) 1.29
STAT3 negatively regulates thyroid tumorigenesis. Proc Natl Acad Sci U S A (2012) 1.23
Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res (2007) 1.22
Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl Immunohistochem Mol Morphol (2003) 1.15
Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Arch (2014) 1.09
mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab (2012) 1.08
Loss of heterozygosity and promoter methylation, but not mutation, may underlie loss of TFF1 in gastric carcinoma. Lab Invest (2002) 1.05
Paraganglioma of seminal vesicle and chromophobe renal cell carcinoma: a case report and literature review. Sao Paulo Med J (2012) 1.04
A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum Pathol (2005) 1.04
Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas. Oncology (2003) 1.03
Multicentre validation study of nucleic acids extraction from FFPE tissues. Virchows Arch (2010) 1.01
Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas. Br J Ophthalmol (2010) 1.01
Telomerase expression and proliferative activity suggest a stem cell role for thyroid solid cell nests. Mod Pathol (2004) 1.01
Intragenic mutations in thyroid cancer. Endocrinol Metab Clin North Am (2008) 1.00
Hürthle (oncocytic) cell tumors of thyroid: etiopathogenesis, diagnosis and clinical significance. Int J Surg Pathol (2005) 1.00
Abdominal inflammatory myofibroblastic tumor a clinicopathologic study with reappraisal of biologic behavior. J Pediatr Surg (2011) 1.00
p63 expression in solid cell nests of the thyroid: further evidence for a stem cell origin. Mod Pathol (2003) 0.99
Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas. Anticancer Res (2008) 0.98
Surgical margin status and prognosis of gastrointestinal stromal tumor. World J Surg (2008) 0.97
BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch (2004) 0.95
Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation. Mol Biol Cell (2008) 0.95
Loss of WNK2 expression by promoter gene methylation occurs in adult gliomas and triggers Rac1-mediated tumour cell invasiveness. Hum Mol Genet (2012) 0.94
Restrictive dermopathy--a lethal congenital laminopathy. Case report and review of the literature. Eur J Pediatr (2008) 0.94
Insights into melanoma: targeting the mTOR pathway for therapeutics. Expert Opin Ther Targets (2012) 0.93
The biology and the genetics of Hurthle cell tumors of the thyroid. Endocr Relat Cancer (2012) 0.92
Poorly differentiated carcinomas of the thyroid gland: a review of the clinicopathologic features of a series of 28 cases of a heterogeneous, clinically aggressive group of thyroid tumors. Int J Surg Pathol (2002) 0.92
Molecular genetics of papillary thyroid carcinoma: great expectations. Arq Bras Endocrinol Metabol (2007) 0.92
Recall of drug utilization depends on subtle structural questionnaire characteristics. Pharm World Sci (2007) 0.91
Cribriform-morular variant of papillary thyroid carcinoma: molecular characterization of a case with neuroendocrine differentiation and aggressive behavior. Am J Clin Pathol (2009) 0.91
DNA copy number profiles of gastric cancer precursor lesions. BMC Genomics (2007) 0.91
B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol (2006) 0.91
A follicular variant of papillary thyroid carcinoma in struma ovarii. Case report with unique molecular alterations. Histopathology (2009) 0.91
Germline succinate dehydrogenase subunit D mutation segregating with familial non-RET C cell hyperplasia. J Clin Endocrinol Metab (2003) 0.90
Angiogenesis and breast cancer. J Oncol (2010) 0.90
Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch (2005) 0.90
Loss of RKIP expression is associated with poor survival in GISTs. Virchows Arch (2009) 0.89
Epidermolytic hyperkeratosis with palmoplantar keratoderma in a patient with KRT10 mutation. Eur J Dermatol (2009) 0.89
Involvement of p53 in cell death following cell cycle arrest and mitotic catastrophe induced by rotenone. Biochim Biophys Acta (2011) 0.89
Congenital composite hemangioendothelioma: case report and reappraisal of the hemangioendothelioma spectrum. J Cutan Pathol (2002) 0.88
Mutated E-cadherin: genomic and functional characterization in thyroid cells from the KAT family. Thyroid (2004) 0.88
Survey of 548 oncogenic fusion transcripts in thyroid tumors supports the importance of the already established thyroid fusions genes. Genes Chromosomes Cancer (2012) 0.88
Mixed gastric carcinomas show similar chromosomal aberrations in both their diffuse and glandular components. Cell Oncol (2006) 0.87
A novel germline SDHB mutation in a gastrointestinal stromal tumor patient without bona fide features of the Carney-Stratakis dyad. Fam Cancer (2012) 0.87
A polymorphism in the promoter region of the selenoprotein S gene (SEPS1) contributes to Hashimoto's thyroiditis susceptibility. J Clin Endocrinol Metab (2014) 0.86
Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas. Melanoma Res (2016) 0.86
BRCA1 deficiency in skin epidermis leads to selective loss of hair follicle stem cells and their progeny. Genes Dev (2012) 0.86
Thyroid hormone as a regulator of tumor induced angiogenesis. Cancer Lett (2010) 0.86
Impact of EGFR genetic variants on glioma risk and patient outcome. Cancer Epidemiol Biomarkers Prev (2011) 0.86
Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer (2009) 0.86
Evaluation of LMI1195, a novel 18F-labeled cardiac neuronal PET imaging agent, in cells and animal models. Circ Cardiovasc Imaging (2011) 0.86
Thyroid hormone receptor beta mutations in the 'hot-spot region' are rare events in thyroid carcinomas. J Endocrinol (2007) 0.85
Immunohistochemical study of heat shock proteins 27, 60 and 70 in the normal human adrenal and in adrenal tumors with suppressed ACTH production. Microsc Res Tech (2003) 0.85
Evaluation of colon cancer histomorphology: a comparison between formalin and PAXgene tissue fixation by an international ring trial. Virchows Arch (2014) 0.85
Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal. Clin Endocrinol (Oxf) (2006) 0.85
Cancer: Small papillary thyroid cancers--is BRAF of prognostic value? Nat Rev Endocrinol (2011) 0.85
Human periprostatic white adipose tissue is rich in stromal progenitor cells and a potential source of prostate tumor stroma. Exp Biol Med (Maywood) (2012) 0.85
Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples. BMC Cancer (2008) 0.85
Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes. J Pathol (2005) 0.85
RET/PTC rearrangement is prevalent in follicular Hürthle cell carcinomas. Histopathology (2012) 0.85
Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs. Histopathology (2009) 0.85
Stimulated thyroglobulin at recombinant human TSH-aided ablation predicts disease-free status one year later. J Clin Endocrinol Metab (2013) 0.84
A stem cell role for thyroid solid cell nests. Hum Pathol (2005) 0.84
Classic Kaposi's sarcoma of the tongue: case report with emphasis on the differential diagnosis. J Oral Maxillofac Surg (2002) 0.83
P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression. Pathol Res Pract (2002) 0.83
Hyaline cell-rich chondroid syringoma: case report and review of the literature. Pathol Res Pract (2002) 0.83
The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma. Hum Pathol (2006) 0.83
Loss of heterozygosity at 19p13.2 and 2q21 in tumours from familial clusters of non-medullary thyroid carcinoma. Fam Cancer (2007) 0.83